IHE is part of a newly established European consortium DO->IT. DO->IT will manage and coordinate the Innovative Medicines Initiative (IMI) comprehensive programme “Big Data for Better Outcomes” (BD4BO). The BD4BO programme aims to improve efficiency in health care, leading to better treatment results and drive development towards value-based pricing and reimbursement models. Leveraging the growing digitization of health care and society at large will help to improve knowledge on the effectiveness of different therapies in clinical practice. The programme is expected to last for at least 5 years.
DO->IT is led by the London School of Economics (LSE), together with Novartis. In total, the consortium has about 30 members, including patient organizations, academia and authorities working side by side with some of the world’s leading pharmaceutical companies. Swedish participants include the Dental and Pharmaceutical Benefits Agency (TLV) and IHE.
During the first two years, the consortium will develop the programme strategy and coordinate the various projects within the programme. So far, activities have started on Alzheimer’s disease and hematologic diseases, but several additional projects are on track, particularly in prostate cancer. The DO->IT consortium will also identify additional areas where there is currently a lack of real-world evidence and establish common rules for how the programme should handle patients’ right to integrity. IHE is expected to take a leading role, particularly regarding the programme strategy.
The BD4BO programme was started in 2015 by IMI. IMI is a joint undertaking between the European Union and the European Federation of Pharmaceutical Industries and Associations (EFPIA) and is often described as the world’s largest public-private partnership.